原发性干燥综合征中淋巴瘤的临床表现、结局及预测因素:来自协调数据集(1981-2021)的结果
该回顾性研究分析了121例符合2016年ACR-EULAR分类标准的原发性干燥综合征(pSS)合并非霍奇金淋巴瘤(NHL)患者,按WHO分类标准诊断。黏膜相关淋巴组织淋巴瘤(MALTL)占76.0%(92/121),10年总生存(OS)率和无事件生存(EFS)率分别为79%和45.5%;弥漫大B细胞淋巴瘤(DLBCL)占9.0%(11/121),10年OS和EFS分别为40.9%和24.2%;结节边缘区淋巴瘤(NMZL)占7%(8/121),10年OS和EFS分别为46%和31%。冷球蛋白血症、灶性评分和pSS诊断时EULAR SS疾病活动指数(ESSDAI)复合指数被证实为MALTL的独立预测因素。
要点
- MALTL占pSS相关淋巴瘤的76.0%(92/121),10年OS率79%、EFS率45.5%。
- DLBCL占9.0%(11/121),10年OS率40.9%、EFS率24.2%;NMZL占7%(8/121),10年OS率46%、EFS率31%。
- 冷球蛋白血症、灶性评分和诊断时ESSDAI复合指数为MALTL独立预测因素。
核心结论
- pSS诊断时存在的常见特征可预测未来淋巴瘤发生,值得制定更密集的随访计划。
研究设计与样本
- 回顾性分析121例根据WHO分类标准诊断为NHL且符合2016年ACR-EULAR pSS分类标准的患者,记录并协调累计临床、实验室、影像学、治疗方案及组织学数据,计算OS和EFS曲线,并应用数据驱动分析建立MALTL预测模型。
主要发现
- MALTL占多数(92/121,76.0%),其次为DLBCL(11/121,9.0%)和NMZL(8/121,7%)。
- MALTL表现为唾液腺定位、局限性疾病,常伴骨髓和淋巴结受累。
- MALTL的10年OS率为79%、EFS率为45.5%;DLBCL的10年OS率为40.9%、EFS率为24.2%;NMZL的10年OS率为46%、EFS率为31%。
- 冷球蛋白血症、灶性评分和pSS诊断时ESSDAI复合指数被证实为MALTL的独立预测因素。
- 尽管MALTL生存前景相对较好,但其临床过程中伴随频繁事件。
关键数值与推荐
- MALTL占92/121(76.0%),DLBCL占11/121(9.0%),NMZL占8/121(7%)。
- MALTL的10年OS率为79%、EFS率为45.5%。
- DLBCL的10年OS率为40.9%、EFS率为24.2%。
- NMZL的10年OS率为46%、EFS率为31%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Primary Sjögren's Syndrome (pSS) carries the highest risk for non-Hodgkin's lymphoma (NHL) development among systemic autoimmune diseases. However, the paucity of data on the long-term survival of those patients and the lack of established predictors for each lymphoma histologic subtype prompted our present study. METHODS: We retrospectively analysed 121 patients diagnosed with NHL according to the WHO classification criteria. All patients fulfilled the 2016 ACR-EULAR classification criteria for pSS. Cumulative clinical, laboratory, radiologic, treatment regimens and histologic data were recorded, harmonized and analysed. Overall survival (OS) and event-free survival (EFS) curves were calculated. A mucosa-associated lymphoid tissue lymphoma (MALTL) prediction model was developed by applying innovative data-driven analysis of clinical features present at the time of pSS diagnosis. RESULTS: MALTLs constituted the majority of lymphomas (92/121, 76.0%) followed by diffuse large B-cell lymphomas (DLBCL) (11/121, 9.0%) and nodal marginal zone lymphomas (NMZL) (8/121, 7%). MALTLs show salivary glands localization, limited disease and often bone marrow and nodal involvement. The 10-year OS and EFS rates were 79% and 45.5% for MALTLs, 40.9% and 24.2% for DLBCL and 46% and 31% for NMZL. Cryoglobulinemia, focus score and the total EULAR SS Disease Activity Index (ESSDAI) composite index at pSS diagnosis were proven independent MALTL predictors. Even though MALTLs have a comparatively good survival outlook, they are accompanied by frequent events throughout their clinical course. CONCLUSIONS: Common features of pSS, present at diagnosis, can predict future lymphomagenesis meriting a more intensive follow-up plan.
引用
- Chatzis LG, Stergiou IE, Goules AV, et al. Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren's syndrome: results from a harmonized dataset (1981-2021). Rheumatology (Oxford). 2022. PMID: 34940812. doi:10.1093/rheumatology/keab939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。